3.0.0 2716 2023-01-12T17:53:00Z 2023-01-12T17:53:00Z House H HR 2007-06-14 110 hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2007-06-14T20:26:56Z Referred to 2007-06-14T14:01:30Z 2007-06-14 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2007-06-14 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2007-06-14 Introduced in House IntroReferral Intro-H 9 Library of Congress 2007-06-14 Introduced in House IntroReferral 1000 9 Library of Congress B001149 Rep. Burton, Dan [R-IN-5] DAN BURTON R IN 5 N H001037 Rep. Herseth Sandlin, Stephanie [D-SD-At Large] Stephanie Herseth Sandlin D SD 0 2007-07-17 False Health Civil Rights and Liberties, Minority Issues Commerce Drug advertising Drug industry Drugs Fines (Penalties) Government Operations and Politics Government publicity Identification devices Intellectual property Labeling Law Packaging Product counterfeiting Right of privacy Science, Technology, Communications Health 00 2007-06-14 Introduced in House 2007-07-23T20:41:45Z Reducing Fraudulent and Imitation Drugs Act of 2007 - Directs the Secretary of Health and Human Services to require prescription drug packaging to incorporate: (1) radio frequency tagging technology or similar trace and track technologies; (2) tamper-indicating technologies; and (3) blister security packaging when possible.

Directs the Secretary to: (1) require that such technologies be used exclusively to authenticate the pedigree of prescription drugs; and (2) prohibit such technologies from containing or transmitting any identifying information of a health care practitioner or consumer, or any advertisement or information about indications or off-label uses.

Requires the Secretary to encourage prescription drug manufacturers and distributors to incorporate: (1) overt optically variable counterfeit-resistant technologies into packaging; and (2) required prescription drug packaging technologies into multiple elements of the physical packaging of the drugs. Requires prescription drug shipments to include a label on the shipping container that incorporates packaging technologies.

Deems a prescription drug to be misbranded if the packaging or labeling of the drug is in violation of a requirement or prohibition of this Act.

Requires the Secretary to publish the National Specified List of Susceptible Prescription Drugs, consisting of not less than 30 of the most frequently counterfeited prescription drugs in the United States.

]]> Reducing Fraudulent and Imitation Drugs Act of 2007 Display Title Reducing Fraudulent and Imitation Drugs Act of 2007 Official Title as Introduced To direct the Secretary of Health and Human Services to require the incorporation of counterfeit-resistant technologies into the packaging of prescription drugs, and for other purposes. Introduced in House IH Short Titles as Introduced Reducing Fraudulent and Imitation Drugs Act of 2007 Introduced in House 2007-06-14T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-110hr2716ih/xml/BILLS-110hr2716ih.xml 2007-06-14 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.